This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Save the date!
November 6–8, 2023Munich, Germany



TOLLYS is a preclinical stage biopharmaceutical company located in Lyon, France, developing a proprietary new generation of synthetic and specific TLR3 agonists for the treatment of patients suffering from multiple types of cancer.

Tollys discovered and patented the first rationally designed specific agonist of TLR3 with a defined sequence of nucleotides synthetized chemically (“TL-532”). Tollys has demonstrated the anti-tumoral and auto-vaccination properties of TL-532 in vitro on cancer cells, in vivo in animal models of cancer and ex vivo on fresh human tumor biopsies (discovery and proof-of-concept data presented at AACR Congress 2022).  

In 2021 TL-532 was named the "Best-in-Class Oncology Innovation 2021" by the international Board of the MATWIN Oncology innovation program ( TLR3 was confirmed as a target of great interest for the treatment of cancer and TL-532 as a unique and first ever potent and specific TLR3 agonist with dual potency on immune and cancer cells.

TL-532 is the smallest and most efficient TLR3 agonist and can be bioconjugated for targeting with antibodies and other carriers.

TL-S01 is the specific and synthetic new generation TLR3 agonist optimized for systemic administration, in preclinical development

We are interested to meet with potential pharma and biotech partners and with potential investors